Study Explores Liver Outcomes After HIV Treatment Switch
March 5, 2026
PASO DOBLE sub-analysis reports steatosis differences at 96 weeks
1 min read
False
Advertisement
Research News
HEK293 Cell Line for rAAV Manufacturing
March 4, 2026
New study reports two-fold improvement in full-to-empty rAAV ratio versus commercial HEK293 line
2 min read
Refining CAR-NK Design
March 4, 2026
Preclinical findings suggest that receptor design and timed kinase inhibition could help strengthen next-generation cell therapies.
1 min read
A Pharmacologic Off-Switch for Split CARs
March 3, 2026
Study describes a venetoclax-regulated off-switch CAR system with dose-dependent control of receptor assembly in vitro and in vivo
2 min read
Oral BTK Inhibitor Shows Disability Benefit in Progressive Multiple Sclerosis Trial
February 17, 2026
Phase 3 results show fenebrutinib matched OCREVUS on disability progression in PPMS
2 min read
First Preclinical Development Candidate for Nucleome Therapeutics
January 19, 2026
First-in-class monoclonal antibody agonist program for inflammation
2 min read
The Post-Pandemic Evolution of Antiviral Research
December 22, 2025
The pandemic catalyzed a transformation in antiviral R&D. From better data to open collaboration, Tetiana Matviyuk of Enamine describes how the landscape has evolved.
3 min read
New Approach Methodologies: Why the Future of Drug Development Must Be Human
By Hayley Gooding
December 18, 2025
NAMs aren’t just a scientific upgrade, but a moral and practical necessity. The tools are ready. The question is: does the industry have the will to use them?
3 min read
Promising Data For Off-the-Shelf Gene-edited Cell Therapy
December 17, 2025
New clinical results outline patient responses to a donor-derived, gene-edited cell therapy in relapsed and refractory T-cell leukemia
2 min read
This Week’s Biopharma News: New Pharma Legislation in Europe
December 16, 2025
Our latest news roundup reports on the oversubscribed financing for Cellular Origins, FDA approval for Amgen, CAR-T cell therapy outcomes, and more
5 min read
